氨基观察-创新药组原创出品作者 | 蔡九微创医疗努力降本增效。7月17日,微创医疗公告,2025年上半年公司优化资源和非核心业务处置,提升运营效率,亏损额预计不超过1.1亿美元。而在去年同期,公司亏损额为1.06亿美元。白蛋白市场迎来新选手。7月18日,据 NMPA官网,禾元生物重组人白蛋白注射液(水稻)(商品名:奥福民)获批上市,用于治疗肝硬化低白蛋白血症(≤30g/L)。该药物是我国首个获批...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.